Unveiling the Future: Nyxoah S A, Addex Therapeutics, and Pyxis Oncology Surge in Consecutive Market Gains

The financial markets are abuzz with excitement as three remarkable companies—I Nyxoah S A, Addex Therapeutics, and Pyxis Oncology—experience consecutive market gains, with NYXH, ADXN, and PYXS boasting impressive increases of 108.88%, 72.48%, and 69.53%, respectively. Join us as we delve into the recent developments of these companies and explore their prospects for the future.

NYXH. Nyxoah S A  +108.88%

Nyxoah S.A., commonly known as Nyxoah, has charted its course for the year 2024, revealing strategic objectives in preparation for upcoming investor engagements.

2024 Strategic Priorities:

1. **Complete DREAM U.S. Pivotal Study Follow-up:** Nyxoah aims to conclude patient follow-up in the DREAM U.S. pivotal study and release efficacy and safety data by early April. Preliminary data presented at SLEEP 2023 showcased promising results, with a 65% AHI responder rate and a 76% ODI responder rate.

2. **Finalize Modular PMA Submission:** The company plans to file the fourth and final module in the modular PMA submission shortly after announcing DREAM results, advancing towards potential success in the regulatory process.

3. **U.S. Commercial Organization Expansion:** Nyxoah is set to accelerate investments in its U.S. commercial organization, gearing up for a late 2024 launch. Recent key appointments, including Francis Kim as Chief Regulatory and Quality Officer, signify a strategic move towards securing a strong market presence.

4. **Complete Enrollment in CCC U.S. Pivotal Study:** Nyxoah is progressing towards completing enrollment in the ACCESS complete concentric collapse (CCC) U.S. pivotal study. Recent investigator-sponsored data in Europe underscores the success of Genio® in treating CCC patients.

5. **Expand Genio Market Share in Europe:** The focus for 2024 includes increasing market penetration of hypoglossal nerve stimulation (HGNS) and expanding Genio market share in Europe. The company anticipates growth through direct-to-consumer (DTC) initiatives, the ResMed commercial partnership in Germany, and geographic expansion.

ADXN Addex Therapeutics Ltd ADR +72.48%

Addex Therapeutics: Allosteric Modulation for Neurological Disorders

Addex Therapeutics is a clinical-stage pharmaceutical company at the forefront of allosteric modulation-based drug discovery. With a focus on neurological disorders, Addex has two key programs in its pipeline: ADX71149 for epilepsy and dipraglurant for post-stroke recovery. The company is also exploring other therapeutic avenues, including chronic cough, stress-related disorders, schizophrenia, and mild neurocognitive disorders.

Dr. Robert Lütjens, Head of Discovery – Biology at Addex, recently presented at the Swiss Equities Baader Conference, providing updates on recent advances in the company’s Central Nervous System (CNS) pipeline. Addex’s commitment to allosteric modulation positions it as a promising player in the evolving landscape of neurological therapeutics.

PYXS Pyxis Oncology Inc +69.53%

Pyxis Oncology: Targeting Difficult-to-Treat Cancers

Pyxis Oncology, a clinical-stage company focused on defeating difficult-to-treat cancers, reported a significant market gain following the announcement of inducement grants under Nasdaq Listing Rule 5635(c)(4). The grants were awarded to Dr. Ken Kobayashi, the newly appointed Chief Medical Officer, in connection with his employment.

Pyxis Oncology is strategically building next-generation therapeutics, including antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs. These therapeutic candidates aim to directly kill tumor cells and address the underlying pathologies of cancer, providing potential mono and combination therapies.

As the market witnesses consecutive gains for Nyxoah S A, Addex Therapeutics, and Pyxis Oncology, the future appears promising for these innovative companies. These companies are well-positioned to make a lasting impact on the healthcare and pharmaceutical industries. Industry enthusiasts alike will be eagerly awaiting further developments as these companies continue to push the boundaries of medical innovation.